CRISPR Therapeutics AG
CRISPR Therapeutics is a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts.
Last Closing Price
January 5, 2018
Goldman Sachs, Piper Jaffray, Barclays
To view the prospectus for CRISPR Therapeutics AG, or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253